Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Monday

Prelude Therapeutics (NASDAQ:PRLD) is expected to announce its Q2 2025 earnings results before the market opens on Monday, August 11th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter.

Prelude Therapeutics (NASDAQ:PRLD) last announced its earnings results on Tuesday, May 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.05. On average, analysts expect Prelude Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Prelude Therapeutics Trading Up 0.1%

NASDAQ:PRLD opened at $0.86 on Friday. The company’s 50-day moving average price is $0.88 and its 200-day moving average price is $0.86. The company has a market cap of $48.41 million, a P/E ratio of -0.51 and a beta of 1.22. Prelude Therapeutics has a twelve month low of $0.61 and a twelve month high of $6.80.

Hedge Funds Weigh In On Prelude Therapeutics

A hedge fund recently raised its stake in Prelude Therapeutics stock. AQR Capital Management LLC boosted its position in shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 170.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 33,823 shares of the company’s stock after purchasing an additional 21,330 shares during the period. AQR Capital Management LLC owned approximately 0.08% of Prelude Therapeutics worth $26,000 at the end of the most recent quarter. Institutional investors own 79.72% of the company’s stock.

Analysts Set New Price Targets

PRLD has been the topic of several research reports. HC Wainwright reissued a “buy” rating and issued a $5.00 price target on shares of Prelude Therapeutics in a research note on Monday, May 5th. JMP Securities reissued a “market outperform” rating and issued a $4.00 price target on shares of Prelude Therapeutics in a research note on Tuesday, April 29th.

About Prelude Therapeutics

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.